Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSafaa Ali
About this trial
aim of the work
1. To evaluate the presence of SF3B1-K700E mutation in acute lymphoblastic leukemia and chronic lymphocytic leukemia. 2. To determine the correlation between the presence of SF3B1-K700E mutation with other laboratory findings.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with acute lymphocytic leukemia or chronic lymphocytic leukemia of both genders at any age.
Disqualifiers
Patients with any other type of malignancies
Trial population
Study will be conducted on peripheral blood samples of 28 acute lymphoblastic leukemia patients, 28 chronic lymphocytic leukemia patients and 28 control.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
84 Participants
are grouped into 3 trial groupsGroup A: all patients group
Group B: cll patients
Group C: control group
Trial outcomes
Primary outcomes
1
1- To evaluate the presence of SF3B1-K700E mutation in acute lymphoblastic leukemia and chronic lymphocytic leukemia using PCR technique
ARMS PCR technique will be used to detect the presence of SF3B1-MUTATION in acute lymphoblastic leukemia and chronic lymphocytic leukemia
Time frame
2 years2
2-To determine the effect of presence of SF3B1-K700E mutation with other laboratory findings.
determine if the presence of SF3B1-mutation can affect the clinical data as severity of disease or organomegaly and laboratory data as count of white blood cells and platalet and hemoglobin level using automated cbc analyser and bone marrow of the patients (cellularity and count of blast cells) and result of flow cytometry
Time frame
two yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Safaa Ali
Lead sponsor
Assiut University
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: